國立虎尾科技大學 |

Cardiac drug safety = a bench to bedside approach /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Cardiac drug safety/ Matthew J. Killeen.
Reminder of title:	a bench to bedside approach /
Author:	Killeen, Matthew J.
Published:	Singapore :World Scientific, : 2012.,
Description:	1 online resource (189 p.)
Notes:	Variability of repolarization.
Subject:	Arrhythmia - Treatment. -
Online resource:	http://www.worldscientific.com/worldscibooks/10.1142/7839#t=toc
ISBN:	9789814317467 (electronic bk.)

Cardiac drug safety = a bench to bedside approach /
Killeen, Matthew J.

Cardiac drug safetya bench to bedside approach /[electronic resource] :Matthew J. Killeen. - Singapore :World Scientific,2012. - 1 online resource (189 p.)

Variability of repolarization.

Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels.

Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr.

ISBN: 9789814317467 (electronic bk.)Subjects--Topical Terms:

972405
Arrhythmia
--Treatment.Index Terms--Genre/Form:

554714
Electronic books.

LC Class. No.: QC903.S86

Dewey Class. No.: 363.738/74

Cardiac drug safety = a bench to bedside approach /
LDR:04524cam a2200349Mi 4500 001 780538
003 OCoLC
005 20140116092643.0
006 m d
007 cr |n|---|||||
008 140325s2012 si o 000 0 eng d
020 $a 9789814317467 (electronic bk.)
020 $a 9814317462 (electronic bk.)
020 $z 9789814317450
020 $z 9814317454
020 $a 1280669225
020 $a 9781280669224
035 $a ocn794328376
040 $a EBLCP $b eng $c EBLCP $d OCLCQ $d LGG $d YDXCP $d N $d IDEBK $d OCLCQ $d CDX $d DEBSZ
050 4 $a QC903.S86
082 0 4 $a 363.738/74 $a 363.73874 $a 615.71
100 1 $a Killeen, Matthew J. $3 972404
245 1 0 $a Cardiac drug safety $h [electronic resource] : $b a bench to bedside approach / $c Matthew J. Killeen.
260 $a Singapore : $b World Scientific, $c 2012.
300 $a 1 online resource (189 p.)
500 $a Variability of repolarization.
505 0 $a Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels.
505 8 $a Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References.
505 8 $a Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts.
505 8 $a Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction.
505 8 $a Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia.
520 $a Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr.
588 $a Description based on print version record.
650 0 $a Arrhythmia $x Treatment. $3 972405
650 0 $a Drugs $x Safety regulations $z Canada. $3 972406
650 2 $a Heart $x drug effects. $3 790629
650 2 $a Drug Toxicity $x prevention & control. $3 972407
655 4 $a Electronic books. $2 local $3 554714
856 4 0 $u http://www.worldscientific.com/worldscibooks/10.1142/7839#t=toc